News | November 10, 2025
Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
The antibody was designed and developed at Abzena’s Cambridge, UK,
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Subscribe To Our Newsletter & Stay Updated
